Literature DB >> 28117913

Quality control of a medicinal larval (Lucilia sericata) debridement device based on released gelatinase activity.

S F Pickles1, D I Pritchard1.   

Abstract

Lucilia sericata Meigen (Diptera: Calliphoridae) larvae are manufactured worldwide for the treatment of chronic wounds. Published research has confirmed that the primary clinical effect of the product, debridement (the degradation of non-viable wound tissue), is accomplished by a range of enzymes released by larvae during feeding. The quality assessment of larval activity is currently achieved during production using meat-based assays, which monitor insect growth and/or the reduction in substrate mass. To support this, the present authors developed a complementary radial diffusion enzymatic assay to produce a visual and measureable indication of the activity of larval alimentary products (LAP) collected under standardized conditions, against a gelatin substrate. Using basic laboratory equipment and reagents, the assay is rapid and suited to high throughput. Assay reproducibility is high (standard deviation: 0.06-0.27; coefficient of variation: 0.75-4.31%) and the LAP collection procedure does not adversely affect larval survival (mortality: < 2%). Because it is both cost- and time-effective, this method is suited to both academic and industrial use and supports good manufacturing and laboratory practice as a quality control assay.
© 2017 The Royal Entomological Society.

Entities:  

Keywords:  Lucilia sericata; debridement; gelatinase; medical device; quality control; wound management

Mesh:

Substances:

Year:  2017        PMID: 28117913     DOI: 10.1111/mve.12220

Source DB:  PubMed          Journal:  Med Vet Entomol        ISSN: 0269-283X            Impact factor:   2.739


  1 in total

1.  Expression of a New Recombinant Collagenase Protein of Lucilia Sericata in SF9 Insect Cell as a Potential Method for Wound Healing.

Authors:  Hamzeh Alipour; Abbasali Raz; Navid Dinparast Djadid; Sedigheh Zakeri
Journal:  Iran J Biotechnol       Date:  2019-12-01       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.